The Exit is Absolute
Buffett is out. The liquidation is total. Berkshire Hathaway has scrubbed its ledger of UnitedHealth Group shares. This was not a tactical trim. It was a strategic execution of a 5.04 million share position. The market is reeling. The signal is deafening. When Omaha exits a sector giant, the floor usually falls away.
The latest 13F filings confirm the move. Berkshire Hathaway no longer holds a single share of the managed care behemoth. This comes at a time when the healthcare sector is grappling with structural shifts in reimbursement and regulatory scrutiny. The move follows a period of heightened volatility for UnitedHealth, which has seen its dominance challenged by both legislative headwinds and internal operational failures.
The Erosion of the Managed Care Moat
UnitedHealth Group has long been considered the invincible flywheel of American healthcare. It owns the insurance. It owns the doctors. It owns the data. Through its Optum subsidiary, it has vertically integrated to a degree that once made it a Buffett favorite. That thesis is now broken. The medical loss ratio (MLR) has become a persistent thorn. Rising costs of care are no longer being offset by premium hikes. The arbitrage is failing.
Regulatory pressure is the primary catalyst. The Department of Justice has intensified its antitrust investigations into the relationship between UnitedHealth’s insurance arm and Optum. The concern is simple. UnitedHealth is accused of funneling patients to its own providers to maximize internal profits while squeezing independent competitors. For a value investor like Buffett, the regulatory risk now outweighs the cash flow stability. The moat is no longer a defense. It is a target.
UnitedHealth Group Stock Price Reaction (May 17 – May 19)
The Optum Paradox
Optum was supposed to be the hedge. When insurance margins tightened, the services side would pick up the slack. This logic held for a decade. It failed in the wake of the Change Healthcare cyberattack, which exposed the systemic fragility of UnitedHealth’s centralized infrastructure. The recovery costs were not just financial. They were reputational. The company’s ability to act as the central nervous system of US healthcare payments was compromised, inviting unprecedented federal oversight.
Medicare Advantage is the second fracture. The Centers for Medicare & Medicaid Services (CMS) have signaled a pivot. Reimbursement rates are being squeezed. The era of easy growth in the private-public healthcare partnership is ending. Berkshire’s exit suggests a belief that the peak of the managed care cycle is in the rearview mirror. Buffett does not wait for the crash. He leaves when the growth story begins to stutter.
Shadows Over the Dow
UnitedHealth is a price-weighted heavyweight in the Dow Jones Industrial Average. Its decline drags the entire index. The liquidation of 5.04 million shares is a liquidity event that forces other institutional players to re-evaluate their positions. We are seeing a rotation out of defensive healthcare and into high-growth tech or distressed energy. The narrative that healthcare is a recession-proof haven is being dismantled in real-time.
The technical indicators are grim. UNH has broken through its 200-day moving average on high volume. This is institutional distribution. According to SEC filings, Berkshire is not the only fund reducing exposure, but they are the most prominent. The question is no longer whether UNH is a buy. The question is who is left to catch the falling knife.
Forward Looking Focus
The next data point to watch is the June 15 Medicare Advantage final rule clarification. If CMS maintains its aggressive stance on rate cuts, the managed care sector will face a multi-year stagnation. UnitedHealth’s ability to maintain its dividend growth will be the ultimate test of its remaining structural strength. Watch the $455 support level. If that breaks, the exit of the Oracle will look like the most prescient move of the decade.
